Xanax and Opioids: Respiratory Depression, Overdose and Treatment

Xanax and opioids can cause profound sedation and life-threatening respiratory depression when their effects overlap. Xanax contains alprazolam, a benzodiazepine. It is not an opioid, but current U.S. prescribing information carries a boxed warning because combining benzodiazepines with opioids can cause respiratory depression, coma and death.

The warning applies across the opioid class. Examples include prescription pain medications such as oxycodone, hydrocodone and morphine, opioid cough medicines such as codeine, medications used to treat opioid use disorder such as buprenorphine and methadone, and illicit opioids such as heroin and fentanyl. The clinical context differs among these drugs, but overlapping central nervous system depression remains important.

If someone who may have taken Xanax and an opioid cannot be awakened or is breathing slowly, irregularly or not at all, treat the situation as a possible opioid overdose. Call emergency services and give naloxone if it is available. Naloxone can reverse the opioid component of an overdose. It does not reverse alprazolam, so significant sedation may remain after breathing improves.

Xanax and Opioids at a Glance

Why Xanax and Opioids Can Be Dangerous Together

Alprazolam and opioids act at different receptor systems. Alprazolam enhances inhibitory signaling at GABA-A receptor complexes. Opioids act primarily at opioid receptors, including mu-opioid receptors involved in pain relief, sedation and respiratory control.

Current Xanax labeling explains that benzodiazepines can worsen opioid-related respiratory depression because the two drug classes affect different sites in the central nervous system that control respiration. The combined effect can produce much deeper sedation than either medication would be expected to produce alone in that person.

Respiratory depression means breathing becomes inadequate for the body’s needs. The person may breathe too slowly, take shallow breaths, develop irregular pauses or stop breathing. As oxygen falls and carbon dioxide rises, consciousness can deteriorate further.

Sedation also affects airway protection. A deeply sedated person may be unable to reposition, cough normally or respond to vomiting. Aspiration, falls and other injuries can occur alongside the direct respiratory danger.

The interaction is not limited to taking two pills at the same moment. Alprazolam and an opioid can remain active for hours, and repeated doses can overlap. A person who takes an opioid earlier in the day and Xanax later can still have clinically important combined exposure.

Which Opioids Interact With Xanax?

The interaction is a drug-class issue, so it extends beyond one opioid brand. Current Xanax prescribing information lists multiple opioid examples, including morphine, buprenorphine, hydromorphone, oxycodone, fentanyl, methadone, codeine, tapentadol and tramadol.

Common real-world combinations include Xanax with prescription pain medications such as oxycodone or hydrocodone. A patient may receive an opioid after surgery, an injury or for another pain condition while already taking alprazolam for panic or anxiety. The fact that both medications came from legitimate prescriptions does not remove the respiratory interaction.

Opioid cough medicines can matter as well. Codeine-containing products and other opioid cough medications add opioid effects even when the person does not think of the medication as a painkiller.

Heroin and illegally manufactured fentanyl create additional uncertainty because dose and composition are not controlled through a regulated pharmacy. Counterfeit pills can add another route of opioid exposure. The separate Xanax and Fentanyl resource covers counterfeit Xanax and unexpected fentanyl exposure in detail.

Xanax With Oxycodone or Hydrocodone

Oxycodone and hydrocodone are opioid analgesics. Both can cause sedation and respiratory depression, and both fall under the same benzodiazepine-opioid warning when used with alprazolam.

A person taking prescribed Xanax should tell the clinician treating pain about the alprazolam prescription before an opioid is started. The prescriber can review whether both drugs are needed, whether another pain strategy is appropriate, how much sedating medication is already being used and whether other risk factors are present.

Risk assessment also includes alcohol, sleep medications, muscle relaxants, other benzodiazepines and additional opioids. Several central nervous system depressants can be active at once even when each came from a different prescription.

There is no universal internet rule stating that waiting a fixed number of hours after Xanax makes oxycodone or hydrocodone safe. Timing depends on dose, repeated use, formulation, metabolism, other medications, age, respiratory health and the clinical reason for both drugs. Someone with prescriptions for both should follow the plan created by the prescribing clinicians and pharmacist.

Who Has Higher Risk From the Combination?

Any overlapping benzodiazepine and opioid exposure can increase respiratory risk. Some clinical factors make that concern more important.

• Higher opioid or benzodiazepine doses
• Repeated dosing or escalating use
• Alcohol use
• Other sedatives, sleep medications or muscle relaxants
• Sleep-disordered breathing such as sleep apnea
• Chronic lung disease or reduced respiratory reserve
• Older age or medical frailty
• History of overdose
• Substance use disorder
• Recent loss of opioid tolerance
• Use of pills or powders from an unregulated supply

Loss of tolerance deserves specific attention. A person returning to opioids after abstinence, detoxification, hospitalization, incarceration or a treatment interruption may be more vulnerable to an opioid dose that was previously tolerated. Adding Xanax or another sedative can increase the danger further.

Individual risk cannot be calculated from one factor alone. A lower prescribed dose does not create a guarantee of safety, and the presence of several risk factors should prompt closer clinical review.

What a Xanax and Opioid Overdose Can Look Like

The most urgent signs involve breathing and responsiveness. Severe opioid toxicity can initially resemble deep sleep, especially when a benzodiazepine is also causing sedation.

• Unable to awaken normally
• Very slow, shallow or irregular breathing
• Stopped breathing
• Blue, gray or unusually pale lips, fingertips or skin
• Pinpoint pupils, although pupils alone should not determine the response
• Limp body or collapse
• Snoring, choking or gurgling in an unresponsive person
• Loss of consciousness

Alprazolam can also cause pronounced drowsiness, impaired coordination, slurred speech, confusion and memory impairment. Mixed intoxication can therefore leave the person severely sedated even when the opioid component is treated.

A witness does not need to identify the exact opioid before responding. If an opioid could be involved and breathing is abnormal, emergency care and naloxone are appropriate.

The Xanax Overdose guide covers alprazolam intoxication and mixed-overdose assessment in more detail.

What Naloxone Can and Cannot Do

Naloxone is an opioid antagonist. It can rapidly reverse opioid-related respiratory depression when an opioid such as oxycodone, hydrocodone, heroin or fentanyl is contributing to the overdose.

Naloxone has no direct reversal effect on alprazolam. A person can begin breathing more normally and still remain very sleepy, confused, poorly coordinated or difficult to engage because the benzodiazepine remains active.

That partial response is one reason emergency evaluation still matters after severe mixed intoxication. Opioid effects can recur, additional sedatives may remain active, and complications such as aspiration, injury or prolonged oxygen deprivation may require treatment.

CDC recommends offering naloxone particularly to people at increased opioid-overdose risk, including people who take benzodiazepines with opioids. The 2025 ASAM-led benzodiazepine tapering guideline also recommends offering opioid overdose reversal medication to patients who are co-prescribed benzodiazepines and opioids.

How Clinicians Approach Prescribed Xanax and Opioids

Some patients have legitimate reasons that led to prescriptions from both drug classes. Severe acute pain can occur in someone who has been taking alprazolam, and abrupt changes to established benzodiazepine treatment can create a separate withdrawal problem.

Current CDC guidance advises particular caution with concurrent opioid and benzodiazepine prescribing and asks clinicians to consider whether the benefits outweigh the risks. Current Xanax labeling advises reserving concomitant prescribing for patients whose alternative treatment options are inadequate, limiting dose and duration to what is required and monitoring for respiratory depression and sedation.

The 2025 benzodiazepine tapering guideline adds a practical review schedule for co-prescribed patients. It recommends reassessing the risks and benefits of continued benzodiazepine prescribing with every related clinical encounter or prescription renewal and at least every three months.

Clinical review may include whether the opioid is still needed, whether the alprazolam is still providing meaningful benefit, whether doses have escalated, whether another sedative has been added, whether the person has experienced excessive daytime sleepiness and whether naloxone is available.

Medication changes should be coordinated rather than improvised. Suddenly stopping an established alprazolam regimen can create benzodiazepine withdrawal, while abruptly discontinuing opioid therapy in a physically dependent patient can also cause withdrawal and destabilization.

Should Someone Stop Xanax Because They Need an Opioid?

Regular alprazolam use can create physical dependence. Current labeling warns that abrupt discontinuation or rapid dose reduction after continued use may cause acute withdrawal reactions that can be life-threatening.

Benzodiazepine withdrawal can include severe anxiety, insomnia, tremor, agitation and sensory symptoms. More severe presentations can include seizures or delirium. A person who has been taking Xanax regularly should therefore discuss any medication change with the treating clinician instead of stopping suddenly in an attempt to make opioid treatment safer.

The appropriate plan may involve continuing the current benzodiazepine temporarily, reducing another sedating medication, changing the pain strategy, beginning a gradual alprazolam taper or making no immediate benzodiazepine change. The decision depends on the reason for treatment, duration of use, dose, withdrawal history and overall risk.

The Xanax Withdrawal resource explains physical dependence, severe withdrawal risks and individualized tapering principles.

Xanax, Buprenorphine and Suboxone

Buprenorphine is an opioid medication used to treat opioid use disorder and, in some formulations, pain. Suboxone contains buprenorphine and naloxone. Because buprenorphine is an opioid, concurrent benzodiazepine use can still increase sedation and respiratory risk.

That risk does not mean a person with opioid use disorder should automatically be denied buprenorphine treatment. FDA advises that buprenorphine and methadone should not be withheld solely because a patient uses benzodiazepines or other central nervous system depressants. CDC repeats the same principle in its opioid prescribing guideline.

The clinical goal is careful medication management. Clinicians assess why the benzodiazepine is being used, whether it is prescribed or obtained outside medical care, the amount and frequency, alcohol use, overdose history, current sedation and whether gradual benzodiazepine reduction is appropriate.

Someone entering buprenorphine treatment should tell the treatment team about Xanax use, including nonmedical use. Hiding benzodiazepine exposure can make dose decisions and overdose-prevention planning less accurate.

Xanax and Methadone

Methadone is a full opioid agonist used for opioid use disorder and pain. It can cause respiratory depression, particularly during treatment initiation, dose changes or when other depressants are present.

Alprazolam adds another central nervous system depressant to the medication picture. Prescribed or nonmedical Xanax use should therefore be part of methadone assessment and ongoing monitoring.

As with buprenorphine, benzodiazepine use should not automatically exclude someone from evidence-based opioid use disorder treatment. Untreated opioid use disorder carries substantial overdose risk. FDA guidance supports continuing access to methadone or buprenorphine while clinicians manage the added benzodiazepine risk.

The treatment plan may include naloxone, more frequent follow-up, coordinated prescribing, toxicology, review of alcohol and other sedatives, treatment of anxiety or panic symptoms and an individualized benzodiazepine taper when the risks of continued alprazolam outweigh the benefits.

Opioid Use Disorder and Xanax Use Can Require Two Separate Assessments

A person who uses opioids and Xanax can have opioid use disorder, benzodiazepine use disorder, physical dependence on one or both drug classes, or a pattern that does not meet criteria for either use disorder. Those possibilities should be separated during assessment.

Physical dependence means the body has adapted to repeated drug exposure and withdrawal can occur when the drug is stopped or substantially reduced. Dependence can develop during appropriately prescribed treatment.

A substance use disorder involves a broader behavioral and functional pattern. Clinicians assess impaired control, craving, unsuccessful attempts to reduce use, hazardous use, continued use despite consequences and the effect on work, relationships and daily responsibilities.

This distinction affects treatment. Someone taking stable prescribed alprazolam who develops opioid use disorder may need evidence-based opioid treatment plus careful benzodiazepine management. Someone obtaining both drugs outside medical care and repeatedly overdosing may need a more intensive polysubstance treatment plan.

Xanax Addiction covers the difference between dependence, misuse and benzodiazepine use disorder in more depth.

What Happens When Both Opioid and Xanax Dependence Are Present?

Withdrawal planning becomes more complex when a person is physically dependent on both opioids and alprazolam. Opioid withdrawal can be extremely uncomfortable and can contribute to rapid return to opioid use. Benzodiazepine withdrawal can become medically dangerous, including seizure and delirium risk.

The timing of treatment therefore matters. A program should identify each substance, the last use, typical amount, prescription status, prior withdrawal symptoms, prior seizures, overdose history and other depressants before assuming that one detox protocol addresses the whole problem.

Evidence-based medication treatment for opioid use disorder may continue while benzodiazepine dependence is managed. A benzodiazepine taper is generally individualized and may extend well beyond the acute opioid-withdrawal period.

Alcohol use deserves direct assessment because alcohol dependence adds another potentially severe withdrawal syndrome. Sleep medications, gabapentinoids, muscle relaxants and other sedatives can also change the safety picture.

When Detox or Residential Treatment May Be Appropriate

Many prescribed medication changes can be managed in outpatient care, but some patterns justify a more structured setting. Level of care depends on withdrawal severity, overdose history, psychiatric stability, medical conditions, housing, support and the ability to use medications safely outside a program.

Medically supervised detox care may be considered when significant benzodiazepine dependence is present, there is a history of withdrawal seizure or delirium, severe withdrawal is developing, several depressants are being stopped, or medical and psychiatric instability require close monitoring.

Residential treatment can provide additional structure after stabilization when repeated opioid or benzodiazepine misuse, recurrent overdose, uncontrolled access to pills, unstable housing or repeated return to use makes outpatient treatment difficult to sustain.

Dual diagnosis treatment is especially relevant when panic disorder, generalized anxiety, depression, trauma symptoms or another psychiatric condition is closely tied to continued Xanax use. Treating the underlying psychiatric problem can reduce pressure to return to uncontrolled benzodiazepine use during opioid recovery.

Detoxification alone is not a substitute for ongoing opioid use disorder treatment when OUD is present. Buprenorphine, methadone and naltrexone are evidence-based medications used in opioid treatment, with the medication choice and timing based on clinical assessment.

Questions to Bring to a Prescriber or Treatment Program

A useful medication review should be concrete. People taking Xanax and an opioid can ask:

• Why am I taking each medication now?
• Do the benefits of both still outweigh the risks?
• Are any other medications I take adding sedation?
• Should naloxone be prescribed or kept at home?
• What overdose signs should family members recognize?
• If Xanax needs to be reduced, what is the individualized taper plan?
• If I have opioid use disorder, what medication treatment is appropriate?
• How will anxiety or panic symptoms be treated if alprazolam changes?
• Do my sleep apnea, lung disease or other medical conditions change the risk?
• What level of care is appropriate if I have already had an overdose or severe withdrawal?

These questions help move the discussion beyond a simple interaction warning. The goal is a coordinated plan for pain, anxiety, opioid use, benzodiazepine dependence and overdose prevention when those issues overlap.

Frequently Asked Questions About Xanax and Opioids

Is Xanax an opioid?

No. Xanax contains alprazolam, which is a benzodiazepine. It can still interact dangerously with opioids because both drug classes can depress the central nervous system.

Can Xanax and opioids slow breathing?

Yes. Current Xanax labeling carries a boxed warning that concomitant benzodiazepine and opioid use can cause profound sedation, respiratory depression, coma and death.

Can you take Xanax with oxycodone?

Alprazolam and oxycodone have a serious interaction involving sedation and respiratory depression. When both are medically necessary, clinicians should evaluate the risks, use the minimum necessary exposure and monitor the patient rather than treating the combination as routine.

Can you take Xanax with hydrocodone?

Hydrocodone is an opioid, so the same boxed warning applies. A patient with prescriptions for both should follow the coordinated plan from the prescribing clinicians and pharmacist.

How long after Xanax can you take an opioid?

There is no universal waiting period that guarantees the interaction is gone. Dose, repeated use, formulation, metabolism, other medications and medical conditions all affect how long clinically important overlap can persist.

Does naloxone reverse Xanax?

No. Naloxone reverses opioid effects. It can restore breathing when an opioid is involved while alprazolam-related sedation continues.

Can someone take Suboxone if they use Xanax?

Buprenorphine and benzodiazepines require careful management because the combination increases sedation and respiratory risk. FDA and CDC guidance says buprenorphine for opioid use disorder should not automatically be withheld solely because a patient uses a benzodiazepine.

Can someone receive methadone if they take Xanax?

Benzodiazepine use increases risk during methadone treatment and needs active management. FDA guidance advises against automatically withholding methadone for opioid use disorder because of benzodiazepine use.

Should Xanax be stopped suddenly before starting opioid addiction treatment?

No universal abrupt-stop approach is appropriate. Regular alprazolam use can create physical dependence, and sudden discontinuation or rapid reduction can cause severe withdrawal, including seizures in some patients.

Does using Xanax with opioids mean someone has an addiction?

No. Co-use establishes an interaction risk, not a substance use disorder diagnosis. Addiction is assessed from the broader pattern of impaired control, craving, harmful use and consequences.

Sources

• DailyMed: Xanax (alprazolam) Prescribing Information: boxed warning, opioid interaction mechanism, dependence and withdrawal.
• FDA: Benzodiazepine Boxed Warning: opioid combination risk, physical dependence, withdrawal and patient-specific tapering.
• CDC Clinical Practice Guideline for Prescribing Opioids for Pain: concurrent benzodiazepine-opioid caution, naloxone and opioid use disorder treatment principles.
• CDC: Patients’ Frequently Asked Questions About Prescription Opioids: prescription opioid examples, benzodiazepine interaction and overdose risk.
• ASAM: Joint Clinical Practice Guideline on Benzodiazepine Tapering: current co-prescribing review, naloxone and benzodiazepine tapering recommendations.
• FDA: Buprenorphine and Methadone With Benzodiazepines: opioid use disorder medications should not be withheld solely because of benzodiazepine or CNS-depressant use.
• SAMHSA: Prescription Opioids and Fake Pills: opioid-overdose education, naloxone and counterfeit prescription-pill context.